Anti-TIM 3 antibody [F38-2E2] (ab104709)


  • Product nameAnti-TIM 3 antibody [F38-2E2]
    See all TIM 3 primary antibodies
  • Description
    Mouse monoclonal [F38-2E2] to TIM 3
  • Tested applicationsSuitable for: Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    recombinant human TIM-3 protein was used as immunogen

  • Positive control
    • Con A stimulated Human PBMCs


  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C long term.
  • Storage bufferPreservative: 0.05% Sodium Azide
    Constituents: 0.05% BSA, PBS
  • Concentration information loading...
  • PurityProtein G purified
  • ClonalityMonoclonal
  • Clone numberF38-2E2
  • IsotypeIgG1
  • Light chain typekappa
  • Research areas


Our Abpromise guarantee covers the use of ab104709 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use 0.5-1µg for 106 cells. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.


  • FunctionCell surface receptor implicated in modulating innate and adaptive immune responses. Generally accepted to have an inhibiting function. Reports on stimulating functions suggest that the activity may be influenced by the cellular context and/or the respective ligand (PubMed:24825777). Regulates macrophage activation (PubMed:11823861). Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance (PubMed:14556005). In CD8+ cells attenuates TCR-induced signaling, specifically by blocking NF-kappaB and NFAT promoter activities resulting in the loss of IL-2 secretion. The function may implicate its association with LCK proposed to impair phosphorylation of TCR subunits, and/or LGALS9-dependent recruitment of PTPRC to the immunological synapse (PubMed:24337741, PubMed:26492563). In contrast, shown to activate TCR-induced signaling in T-cells probably implicating ZAP70, LCP2, LCK and FYN (By similarity). Expressed on Treg cells can inhibit Th17 cell responses (PubMed:24838857). Receptor for LGALS9 (PubMed:16286920, PubMed:24337741). Binding to LGALS9 is believed to result in suppression of T-cell responses; the resulting apoptosis of antigen-specific cells may implicate HAVCR2 phosphorylation and disruption of its association with BAG6. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens. Expressed on Th1 cells interacts with LGALS9 expressed on Mycobacterium tuberculosis-infected macrophages to stimulate antibactericidal activity including IL-1 beta secretion and to restrict intracellular bacterial growth (By similarity). However, the function as receptor for LGALS9 has been challenged (PubMed:23555261). Also reported to enhance CD8+ T-cell responses to an acute infection such as by Listeria monocytogenes (By similarity). Receptor for phosphatidylserine (PtSer); PtSer-binding is calcium-dependent. May recognize PtSer on apoptotic cells leading to their phagocytosis. Mediates the engulfment of apoptotic cells by dendritic cells. Expressed on T-cells, promotes conjugation but not engulfment of apoptotic cells. Expressed on dendritic cells (DCs) positively regulates innate immune response and in synergy with Toll-like receptors promotes secretion of TNF-alpha. In tumor-imfiltrating DCs suppresses nucleic acid-mediated innate immune repsonse by interaction with HMGB1 and interfering with nucleic acid-sensing and trafficking of nucleid acids to endosomes (By similarity). Expressed on natural killer (NK) cells acts as a coreceptor to enhance IFN-gamma production in response to LGALS9 (PubMed:22323453). In contrast, shown to suppress NK cell-mediated cytotoxicity (PubMed:22383801). Negatively regulates NK cell function in LPS-induced endotoxic shock.
  • Tissue specificityExpressed in T-helper type 1 (Th1) lymphocytes. Expressed on regulatory T (Treg) cells after TCR stimulation. Expressed in dendritic cells and natural killer (NK) cells. Expressed in epithelial tissues. Expression is increased on CD4+ and CD8+ T-cells in chronic hepatitis C virus (HCV) infection. In progressive HIV-1 infection, expression is up-regulated on HIV-1-specific CD8 T-cells.
  • Involvement in diseaseMay be involved in T-cell exhaustion associated with chronic viral infections such as with human immunodeficiency virus (HIV) and hepatitic C virus (HCV).
  • Sequence similaritiesBelongs to the immunoglobulin superfamily. TIM family.
    Contains 1 Ig-like V-type (immunoglobulin-like) domain.
  • Post-translational
    O-glycosylated with core 1 or possibly core 8 glycans.
    Phosphorylated on tyrosine residues; modestly increased after TCR/CD28 stimulation. Can be phosphorylated in the cytoplasmatic domain by FYN (By similarity). Phosphorylation at Tyr-265 is increased by stimulation with ligand LGALS9.
  • Cellular localizationMembrane. Cell junction. Localizes to the immunological synapse between CD8+ T-cells and target cells.
  • Information by UniProt
  • Database links
  • Alternative names
    • FLJ14428 antibody
    • HAVcr-2 antibody
    • Havcr2 antibody
    • HAVR2_HUMAN antibody
    • Hepatitis A virus cellular receptor 2 antibody
    • Kidney injury molecule 3 antibody
    • KIM 3 antibody
    • KIM3 antibody
    • T cell immunoglobulin and mucin domain containing 3 antibody
    • T cell immunoglobulin mucin 3 antibody
    • T-cell immunoglobulin and mucin domain-containing protein 3 antibody
    • T-cell immunoglobulin mucin family member 3 antibody
    • T-cell immunoglobulin mucin receptor 3 antibody
    • T-cell membrane protein 3 antibody
    • Tim 3 antibody
    • TIM-3 antibody
    • TIM3 antibody
    • TIMD-3 antibody
    • TIMD3 antibody
    see all

Anti-TIM 3 antibody [F38-2E2] images

  • Cell surface staining of unstimulated (A) and Con A stimulated (B) Human PBMCs with 0.6 ug of purified Human TIM 3 antibody (Red) and mouse IgG1 isotype control (Green). A cell surface flow kit and PE-conjugated secondary antibody were used for this test. Cells were not fixed for testing.

References for Anti-TIM 3 antibody [F38-2E2] (ab104709)

ab104709 has not yet been referenced specifically in any publications.

Product Wall

The PBMCs in the flow experiment were treated with ConA (Concanavalin A) at 10 ug/ml/million cells for 60 hours.